Introduction
============

The identification of cancer-associated genes is crucial for understanding the molecular mechanisms that are involved in tumorigenesis and tumor development. These genes may contribute to or drive cancer development by their involvement in the functions or pathways that allow cancer cells to evade growth control, metastasis or invasion ([@b1-ol-06-03-0811]).

In the past decade, a number of cancer-associated genes have been identified using rapidly evolving biotechnologies, particularly high-throughput techniques, including gene expression microarrays and proteomics ([@b2-ol-06-03-0811]). For example, known and novel breast cancer genes have been identified using microarray-based comparative genomic hybridization ([@b3-ol-06-03-0811]). Colorectal cancer-associated genes have also been identified using combined computational methods ([@b4-ol-06-03-0811]) and deep transcriptome sequencing ([@b5-ol-06-03-0811]). Certain genes are well-known biomarkers in particular cancers, including BRCA1 and BRCA2 in breast cancer ([@b6-ol-06-03-0811]), PSA in prostate cancer ([@b7-ol-06-03-0811]) and WFDC2 in ovarian cancer ([@b8-ol-06-03-0811]). The associated biological functions of these genes provide clues for the research into cancer biology. However, the few cancer biomarkers that have identified do not act as individual units to perform biological functions. Through the development of sequencing techniques, integrated omics profiles provide the opportunity to identify additional cancer genes. Therefore, it is necessary to understand the mechanisms underlying tumorigenesis at an integrative level.

Public resources, including the public (GenBank, UniGene, Swiss_Prot) and ontological \[Gene Ontology,(GO) consortium and Kyoto Encyclopedia of Genes and Genomes, (KEGG)\] databases, currently offer complementary information for cancer gene identification ([@b9-ol-06-03-0811]). Furthermore, the increasing omics studies of human cancer have produced useful datasets, resulting in the establishment of cancer-associated databases. The Cancer Genome Anatomy Project (CGAP) aims to determine the gene expression profiles of normal, precancerous and cancerous cells (<http://cgap.nci.nih.gov>). The Cancer Genome Project uses human genome sequencing in order to identify the genes that are involved in the development of human cancer (<http://www.sanger.ac.uk/genetics/CGP>). The Cancer Genome Atlas (TCGA) accelerates our understanding of the molecular basis of cancer (<http://cancergenome.nih.gov>). Other derived cancer databases are also publicly available.

Among these online resources, the UniGene database (NCBI GeneBank; <http://www.ncbi.nlm.nih.gov/unigene>) allows the use of Digital Differential Display (DDD, <http://www.ncbi.nlm.nih.gov/UniGene/ddd.cgi>) for the rapid identification of genes whose expressions are altered between tissue types. The UniGene database includes expressed sequences from diverse species-, organ- and disease-derived cDNA libraries. The availability of various human cancer libraries in the UniGene database provides a platform for the rapid identification of selectively-expressed cancer genes.

The present study compares the expressed sequence tags (ESTs) that were identified in 15 types of cancer using the DDD tool. The differentially-expressed genes were bioinformatically evaluated for potential biological functions and pathways, and their expressions were evaluated in the human epididymis. These genes may be involved in regulating the initiation, development and progression of cancer, and may provide potential targets or markers for cancer prognosis, diagnosis, prevention and treatment.

Materials and methods
=====================

DDD analysis
------------

The DDD tool was used to screen the selectively-expressed genes in various cancer types using the UniGene database to compare the number of times that sequences from the libraries were assigned to a particular UniGene cluster. The selected 15 types of human cancer libraries were for adrenal, bladder, breast, cervical, colorectal, esophageal, germ cell, glioma, head and neck, kidney, liver, lung, ovarian, pancreatic tumor and prostate cancer. The statistically significant differences in the EST counts between the cancer groups were determined using the Fisher's exact test. P\<0.05 was considered to indicate a statistically significant difference.

Gene ontological analysis
-------------------------

All selectively-expressed cancer genes were broadly classified into several catalogs according to the GO annotation ([www.geneontology.com](www.geneontology.com)) and the functions reported in the literature.

Enrichment bioinformatics analysis
----------------------------------

The protein identifiers (IDs) were uploaded to the Database for Annotation, Visualization and Integrated Discovery (DAVID; <http://david.abcc.ncifcrf.gov>) and the enrichment analyses of the GO terms, including the biological process, molecular function and cellular component, were performed using the functional clustering annotation tools. The default options with a high classification stringency were used. Finally, the cluster names were extracted from the most biologically relevant GO term that was assigned to that cluster.

Pathway analysis
----------------

Ingenuity pathway analysis v9.0 (IPA; [www.ingenuity.com](www.ingenuity.com); Ingenuity Systems, Redwood City, CA, USA) was used to analyze the pathways and networks that the cancer-associated proteins were involved in. The following settings were used: Reference set, ingenuity knowledge base (genes only); network analysis, direct and indirect relationships; 35 molecules per network; and 25 networks used per analysis. For all species, tissues and cell lines were used for the analysis. The IPA used the Fisher's exact test to determine the significant pathways linked to the input protein set compared with the whole ingenuity knowledge base.

Further characteristics of cancer-associated genes compared with the published literature
-----------------------------------------------------------------------------------------

Highly-expressed human testicular and epididymal genes from a previous study ([@b10-ol-06-03-0811]--[@b12-ol-06-03-0811]) were compared with the present data. The overlapping epididymal genes were further characterized using microarray annotation (<http://humanet.scbit.org/index.jsp>). Secretory proteins and cell surface proteins are considered to be promising biomarkers. All cancer-associated proteins were compared with the serum/plasma proteome ([@b13-ol-06-03-0811]) in order to select the secretory proteins, and were also compared with the cell surfaceome ([@b14-ol-06-03-0811]) to select the cell surface proteins. A GO annotation was used to further filter the results.

Results
=======

Summary of selectively-expressed genes in human cancers
-------------------------------------------------------

The statistical comparison of the ESTs among the various human cancer libraries was performed using the DDD tool. A total of 15 human cancer types and 208 libraries(1,196,901 ESTs) were selected ([Table I](#tI-ol-06-03-0811){ref-type="table"}). The genes that were significantly expressed in the various cancer types were termed the selectively-expressed cancer genes, and those that were uniquely expressed in one given cancer type were termed the uniquely-expressed cancer genes. A total of 1,904 selectively-expressed human cancer genes were identified in the 15 cancer types, of which 274 were uniquely-expressed cancer genes ([Fig. 1](#f1-ol-06-03-0811){ref-type="fig"}).

Bioinformatics analysis
-----------------------

The functional classification analysis showed that the majority of the selectively-expressed cancer genes were associated with binding (34%) and catalytic (27%) activity. Within the 274 uniquely-expressed cancer genes, non-related proteins were associated with antioxidant, motor or translation regulator activity functions ([Fig. 2](#f2-ol-06-03-0811){ref-type="fig"}).

The domain analysis using the DAVID functional annotation tool from the PIR-superfamily classification system identified 13 and nine statistically significant domains in the selectively- and uniquely-expressed cancer genes, respectively. The common domains among the genes were cytochrome P450 CYP2D6 (PIRSF000045), serpin (PIRSF001630) and apolipoprotein A-I (PIRSF002367).

To map the major functional categories, all selectively-expressed cancer genes were grouped into several functional clusters using the functional annotation clustering tool (DAVID). The analysis revealed seven major functional clusters, including i) ribosome, ii) extracellular region, iii) cell adhesion, iv) acute-phase response, v) peptidase inhibitor activity, vi) regulation of cell death and vii) vasculature development.

An analysis of the pathway and the network was performed using IPA. A total of 21 statistically significant pathways were present in the selectively-expressed cancer genes ([Table II](#tII-ol-06-03-0811){ref-type="table"}) and 25 networks were generated. Certain functions were linked to more than three of the 25 networks and mainly included cancer development, cell death, the cell cycle, genetic disorder formation and cellular assembly and organization. The cancer category consists of numerous subcategories of which tumorigenesis is the largest.

Comparison analysis
-------------------

Certain genes that are highly-expressed in the testes or epididymis are promising markers for cancer ([@b15-ol-06-03-0811],[@b16-ol-06-03-0811]). Of the 1,904 selectively-expressed genes, 52 were highly-expressed in the human testes and 30 in the epididymis. Of the 274 uniquely-expressed genes, 15 were highly-expressed in the human testis and 22 in the epididymis. A total of 360 secretory and 272 surface proteins were identified as potential biomarkers that corresponded with the selectively-expressed cancer genes.

Characteristics of highly-expressed cancer genes in the human epididymis
------------------------------------------------------------------------

Of the 274 highly-expressed genes in the human epdidymis, 22 exhibited distinct spatial and temporal expression patterns ([Table III](#tIII-ol-06-03-0811){ref-type="table"}). According to the microarray data analysis (<http://humanet.scbit.org/index.jsp>), three genes were highly expressed in the caput epididiymis, seven in the corpus epididymis and three in the cauda epididymis. Seven genes showed higher expression levels in the aged males.

Discussion
==========

The identification of genomic markers that are associated with the progression of cancer is a key target in the field of cancer research. Genes that are selectively-expressed in cancer cells are promising targets for the development of new diagnostic and therapeutic markers ([@b17-ol-06-03-0811]). An ideal way to identify and characterize cancer-associated genes and their biological functions is to consolidate data from multiple comparable studies in order to perform an integrative analysis.

In the present study, cDNA libraries from 15 human cancer types were integrated for a statistical comparison. Through the utilization of the DDD tool, which screens statistically differentially-expressed genes between different libraries, a total of 1,904 selectively-expressed cancer genes were obtained, including 274 uniquely-expressed cancer genes within various cancer types. Certain genes are well-known to be specifically expressed in certain cancers, including WFDC2, which is uniquely-expressed in ovarian tumors and may be a promising marker in the diagnosis of ovarian carcinoma ([@b18-ol-06-03-0811]). A systematic bioinformatics analysis revealed significant biological functions that were enriched among these genes. These enriched functions or pathways will provide clues for further studies in cancer biology and may lead to the development of new diagnostic and therapeutic markers.

The functional characteristic analysis showed that the selectively-expressed genes mainly performed catalytic and binding activities. These genes shared common functional domains. Cytochrome P450 is a key enzyme domain in cancer formation and treatment ([@b19-ol-06-03-0811]), and the serpin domain contains cancer-related functions that are involved in tumorigenesis by regulating differentiation or inhibiting proteinases ([@b20-ol-06-03-0811]). Apolipoprotein A-I plays a significant role in the progression of ovarian cancer ([@b21-ol-06-03-0811]) and cholangiocarcinoma ([@b22-ol-06-03-0811]). These proteins are associated with the processes involved in cancer development.

The functional clustering analysis identified the main cellular components and biological process clusters that were enriched in the cancer genes. The ribosomal cluster, which is essential for protein synthesis, was the first to be identified in the analysis. It has also been reported that the ribosomal proteins contain certain extraribosomal functions, including those of apoptosis, DNA repair and RNA splicing and modification ([@b23-ol-06-03-0811]). Alterations in ribosome biogenesis is a cause of neoplastic transformation ([@b24-ol-06-03-0811]). Ribosomal protein expression has been shown to be differentially regulated in human colorectum carcinoma, in which ribosomal protein L7 has a neuroendocrine function ([@b25-ol-06-03-0811]). Notably, the selectively-expressed genes that corresponded to the ribosomal proteins were not specifically expressed in certain cancer types.

Cell adhesion molecules are known to play key roles in cancer progression through alterations of cell-cell and cell-extracellular matrix (ECM) adhesions, resulting in cancer cell migration, invasion and proliferation. In the present study, 24 cadherins, including 20 protocadherins and five integrins, were selectively expressed in the cancer cells. E-cadherin is expressed in normal epithelial tissues, but its suboptimal expression has been suggested to be associated with cancer invasion. E-cadherin immunohistochemistry is useful in diagnosing breast cancer ([@b26-ol-06-03-0811]). However, P-cadherin is frequently highly expressed in high-grade breast tumors ([@b27-ol-06-03-0811]). Further studies of these cell adhesion molecules may provide supporting information for the mechanisms of cancer cell interactions and metastatic activities.

The enriched functions of the cancer-associated genes are involved in various stages of cancer development and progression by participating in numerous cellular pathways or networks. Through IPA analysis, 21 significant pathways were identified, which corresponded to the enriched functional clusters.

Notably, 37 of the 274 uniquely-expressed genes were highly expressed in the human testes and epididymis. The cancer/testis genes that displayed a restricted expression in the testis and certain cancers are promising biomarkers. In total, \>200 cancer/testis genes have been identified in the Cancer-Testis (CT) Antigens database (<http://www.cta.lncc.br>). The epididymis is subjected to rare tumors through several potential mechanisms. Certain selectively-expressed genes in the epididymis have spatial and temporal expression patterns for sperm maturation. The alternative expression levels of these genes in certain organs may act as an indicator of cancer development, including WFDC2 in ovarian cancer ([@b28-ol-06-03-0811]), ADAM29 and ADAM7 in melanoma ([@b29-ol-06-03-0811]) and Eppin in prostate cancer ([@b30-ol-06-03-0811]). However, to the best of our knowledge, no studies have reported the association between the highly-expressed epididymal genes and cancer. In the present study, it was hypothesized that certain genes that were strictly expressed in the epididymis may play specific roles in cancer biology.

In conclusion, the present study identified and characterized human cancer-associated genes and their biological functions. The genes that were differentially expressed in various cancer types mainly functioned as ribosomal proteins, enzymes, receptors, secretory proteins and cell adhesion molecules. The results provide a new insight into cancer biology and a new perspective into the involvement of highly-expressed epididymal genes in cancer biomarkers.
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###### 

Summary of libraries used in the present study.

  Cancer type           Libraries   ESTs
  --------------------- ----------- --------
  Adrenal tumor         5           12384
  Bladder carcinoma     2           8752
  Breast tumor          16          88917
  Cervical tumor        5           38138
  Colorectal tumor      24          87951
  Esophageal tumor      4           8672
  Germ cell tumor       26          259108
  Glioma                15          99668
  Head and neck tumor   24          81627
  Kidney tumor          13          68473
  Liver tumor           24          102783
  Lung tumor            15          139981
  Ovarian tumor         15          61470
  Pancreatic tumor      9           90266
  Prostate cancer       11          48711

EST, expressed sequence tags.

###### 

Enriched pathways associated with selectively-expressed cancer genes.

  Pathways[a](#tfn2-ol-06-03-0811){ref-type="table-fn"}   EST count   Percentage   P-value
  ------------------------------------------------------- ----------- ------------ --------------
  hsa03010: Ribosome                                      76          4.33         1.50×10^−53^
  hsa04610: Complement and coagulation cascades           33          1.88         3.60×10^−11^
  hsa04512: ECM-receptor interaction                      28          1.59         9.53×10^−06^
  hsa00010: Glycolysis/Gluconeogenesis                    22          1.25         2.21×10^−05^
  hsa00360: Phenylalanine metabolism                      12          0.68         4.83×10^−05^
  hsa04612: Antigen processing and presentation           23          1.31         1.31×10^−03^
  hsa04510: Focal adhesion                                43          2.45         2.60×10^−03^
  hsa00982: Drug metabolism                               18          1.02         3.06×10^−03^
  hsa04115: p53 signaling pathway                         19          1.08         3.55×10^−03^
  hsa03320: PPAR signaling pathway                        19          1.08         4.21×10^−03^
  hsa05010: Alzheimer's disease                           34          1.94         1.16×10^−02^
  hsa00350: Tyrosine metabolism                           13          0.74         1.25×10^−02^
  hsa00480: Glutathione metabolism                        14          0.80         1.44×10^−02^
  hsa00030: Pentose phosphate pathway                     9           0.51         1.49×10^−02^
  hsa00190: Oxidative phosphorylation                     28          1.59         1.54×10^−02^
  hsa05130: Pathogenic *Escherichia coli* infection       15          0.85         1.87×10^−02^
  hsa03050: Proteasome                                    13          0.74         2.11×10^−02^
  hsa04530: Tight junction                                28          1.59         2.24×10^−02^
  hsa05012: Parkinson's disease                           27          1.54         2.25×10^−02^
  hsa05416: Viral myocarditis                             17          0.97         2.74×10^−02^
  hsa05215: Prostate cancer                               20          1.14         2.94×10^−02^

P\<0.05.

EST, expressed sequence tags; ECM, extracellular matrix; PPAR, peroxisome proliferator-activated receptor.

###### 

Spatial and temporal expression of 22 genes that were highly-expressed in the human epididymis.

  Gene symbol   Accession no.   Spatial expression   Temporal expression   Broad functions                     
  ------------- --------------- -------------------- --------------------- ----------------- ----- ----- ----- -------------------------------
  ALDH3B2       NM_001031615    ++                   +++                   ++                \+    ++    +++   Aldehyde dehydrogenase family
  ANO9          NM_001012302    \+                   +++                   \+                \+    +++   ++    Ion transport
  C1QL1         NM_006688       +++                  ++                    \+                \+    ++    \+    Locomotory behavior
  CYB561        NM_182580       ++                   +++                   +++               \+    +++   ++    Electron transport
  ECM1          NM_004425       \+                   +++                   ++                \+    ++    +++   Signal transduction
  EPN3          NM_017957       ++                   ++                    \+                \+    ++    +++   lipid binding
  GABRP         NM_014211       ++                   ++                    \+                +++   \+    ++    Ion transport
  GNAS          NM_000516       +++                  +++                   +++               ++    +++   ++    Signal transduction
  GP1BB         NM_000407       ++                   \+                    \+                \+    ++    \+    Cell adhesion
  GSN           NM_001127665    \+                   ++                    +++               \+    +++   ++    Calcium ion binding
  NME2          NM_001018137    +++                  ++                    +++               ++    ++    ++    Transcription regulation
  NPC2          NM_006432       +++                  +++                   +++               ++    +++   +++   Lipid metabolism
  NPFF          NM_003717       ++                   +++                   \+                \+    ++    +++   Receptor binding
  PKM2          NM_002654       +++                  +++                   ++                ++    +++   +++   Glycolysis
  PKP3          NM_007183       ++                   +++                   \+                \+    ++    ++    Cell adhesion
  RPL41         NM_021104       +++                  +++                   +++               +++   +++   +++   Ribonucleoprotein
  RPS24         NM_001026       +++                  ++                    ++                ++    +++   ++    Ribonucleoprotein
  SEMA4A        NM_022367       ++                   +++                   \+                \+    ++    +++   Receptor activity
  TG            NM_003235       ++                   ++                    \+                \+    ++    +++   Signal transduction
  USH1G         NM_173477       ++                   \+                    +++               ++    ++    ++    Actin cytoskeleton
  WFDC2         NM_006103       \+                   +++                   ++                \+    ++    +++   Protease inhibitor
  ZNF750        NM_024702       +++                  ++                    +++               \+    +++   ++    Transcription regulation

The expression level of each gene is graded into three levels, strong (+++), moderate (++) and weak (+).
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